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CONTROLLED RELEASE STENTS FOR 
RESTENOSIS 
Robert J. Levy, MD 
The Children Hospital ofPhiladelphia 
Philadelphia, Pa 
Expandable stents used for the relief o f  arterial 
obstruction have led to major progress in interven- 
tional cardiology, especially the treatment o f  coronary 
artery disease. Stents mechanically relieve obstructive 
vascular disease, thereby providing at least short-term 
efficacy. However, a number o f  concerns exist con- 
cerning stents, especially with respect o the continu- 
ing presence of  underlying vascular disease in stented 
arteries, and the recognized existence of  stent-related 
pathology in the form of  in-stent restenosis. 
One solution to this problem has been to consid- 
er the prospect of  stent mediated rug delivery. This 
approach is based on the hypothesis that the frame- 
work o f  a vascular stent can be used as a support for 
a polymer drug delivery system, which could provide 
a therapeutic agent to the arterial wall underlying the 
expanded stent, There are a number o f  challenges to 
this approach. First o f  all, drug delivery preparations 
must be in and of  themselves expandable, to conform 
to the changing dimensions o f  the stent on expan- 
sion. Furthermore, the delivery capacity o f  the stent, 
due to its thin framework, is limited. Thus, it is o f  
importance to identify drugs with a very high poten- 
cy to mass ratio to optimize drug effects. 
Furthermore, the duration o f  drug delivery may also 
be a problem in terms of  the finite capacity o f  the 
stent to contain a relevant herapeutic agent. 
All o f  the above considerations are based on the 
premise that the optimal therapeutic approach is at 
some point understood. At present, this is not the 
case. Nevertheless, ome general principles related to 
stent-mediated drug delivery have been formulated 
and have been investigated in experimental studies. 
Since a major component  of in-stent restenosis i  
smooth muscle cell proliferation, several successful 
therapeutic studies have been carried out using phar- 
maceutical agents designed to inhibit smooth mus- 
cle cell proliferation. The most promising drug used 
in this approach as been the anticancer agent Taxol. 
Taxol is highly potent  and also highly toxic. 
Nevertheless, in experimental studies the inhibition 
o f  smooth muscle cell proliferation in stented arter- 
ies receiving a Taxol delivery stent is significant and 
has led to device technology development)  
Another promising approach, from the point o f  
view of  potency and long-acting therapeutic effects, 
is the gene delivery stent. Two model systems have 
been considered thus far. In  one approach, an 
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adenoviral delivery stent has been formulated and 
has been shown to successfully deliver an adenovirus 
providing a reporter gene to the arterial wall of 
stented animals. 2 However, the adenoviral delivery 
system failed to adequately localize the vector in 
these studies, with widespread transduction i volv- 
ing multiple organ systems. Our laboratory has been 
involved in a plasmid DNA delivery stent, with a 
stent coating based on a polymeric emulsion solvent 
casting system. 3 This particular DNA system has 
been shown to have efficient expression of a reporter 
gene (green fluorescent protein [GFP]) in the arter- 
ial wall, with little evidence ofdistal spread per PCR. 
Recent therapeutic studies have also indicated 
expression of efficacious genetic onstructs in stent- 
ed pig coronary arteries. 
In conclusion, controlled release drug delivery 
stents offer a promising approach to both treating 
underlying arterial disease, as well as preventing in- 
stent restenosis. 
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RECENT PROGRESS IN POLY(ETHYLEN- 
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Rice University 
Houston, Tex 
The major aim of gene therapy is to deliver genet- 
ic material into cells to alter their function, usually for 
the benefit of an entire organism. The genetic mater- 
ial can be either DNA or RNA, and the altered func- 
tion can be an increase or a decrease in the production 
of a protein. The protein is not restricted to being a 
natural product of the host cells, and the host cells are 
not required to be functioning as a part of the whole 
organism at the time of transfection. Fundamental 
problems involve deciding on and isolating the gene 
to deliver, getting it into the cells of interest, and 
achieving expression of the gene once it has entered 
the cells. The field of gene delivery focuses on the lat- 
ter two of these goals and has spawned aggressive 
research in many laboratories throughout the world. 
Fundamcntal pproaches to gene delivery can be 
classified as viral or nonviral. Of the nonviral methods, 
chemicals uch as cationic lipids and polycations have 
been examined in great detail. One of the most suc- 
cessful polycations used in gene delivcry research today 
is poly(ethylenimine) (PEI), which has been widely 
uscd for years in the paper industry. PEI is a highly 
polycationic synthetic polymer that is available in both 
linear and branched forms. It is known to condense 
DNA in solution, forming complexes that are readily 
endocytosed by many cell types. An overview of PEI 
chemistry, PEI /DNA characterization, and transfec- 
tion issues is given in reference 1. This abstract will 
serve to briefly introduce some of the most recent 
developments in PEI-mediated transfection that were 
not covered at the time of the review. 
One of the advantages of  using nonviral over 
viral gene carriers is that the nonviral vectors are not 
architecturally constrained to delivering plasmids at 
or below a given size. It has recently been shown 
that PEI and PLL are both able to deliver yeast arti- 
ficial chromosomes (YACs) of 2.3 Mb into mam- 
malian cells. 2 PEI's ability to compact its carried 
DNA appears to be an important factor in delivering 
large DNA constructs, as shown in the same experi- 
ments, where 67% of the successful PLL-mediated 
transfections suffered amage to the delivered chro- 
mosomes. Compare this to PEI-mediated elivery, 
where 0% of the successful transfections involved 
damage to the delivered YACs. 2 
The condensation of DNA by PEI is important 
for the delivery of smaller plasmids, as well. Whether 
administered in vitro or in vivo, there is potential for 
the PE I /DNA complexes to be exposed to degrada- 
rive nucleases. In the comparison of PEI with PLL, 
it has been shown that PEI offers vastly greater pro- 
tection to transported DNA against degradation by 
DNase i and DNase 2. 3 In these experiments, PEI 
helped preserve DNA, intact, in all conditions test- 
ed, even when the complexes were exposed to 25 to 
50 units of enzyme for 24 hours. Other nonviral 
transfection agents have been shown to offer protec- 
tion below the level given by PEI. For instance, the 
liposome forming agent dioctadecylamidogly- 
cylspermine (DOGS) (also known as Transfectam), 
while offering resistance to DNA against nuclease 
digestion, offered such protection at a level signifi- 
cantly lower than what was observed for linear PEI. 4 
Intuitively, the degradation of delivered DNA can 
lower the ultimate level of transgene xpression, so 
protection of the DNA during delivery is an impor- 
tant consideration toward transfection. 
PEI is not the ideal transfection agent, however. 
